Rodica Busui, MD, PhD is Professor and Chief of the Division of Endocrinology, Diabetes and Clinical Nutrition, Director of the Harold Schnitzer Diabetes Health Center , and the Jordan Schnitzer Endowed Chair in Diabetes at the Oregon Health and Science University (OHSU). She is also the 2023 President for Medicine and Science of the American Diabetes Association (ADA), Professor Emeritus at the University of Michigan, and an internationally recognized leader in the field of diabetes and diabetes complications. Her research interests involve chronic complications of diabetes, including diabetic neuropathy, diabetic foot complications, diabetic kidney disease, heart failure , cardiovascular disease, as well as use of novel technologies for diabetes management. She has been PI and member of the Steering Committee in many landmark diabetes clinical trials funded by NIH, foundations or Industry including: Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), PERL trial: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes, Action to Control Cardiovascular Risk in Diabetes (ACCORD), Bypass Angioplasty Revascularization Investigation Type 2 Diabetes (BARI 2D), Glycemia Reduction Approaches for Diabetes: A Comparative Effective Study (GRADE), T1D Exchange, REPLACE-BG, Wireless Interventions for Seniors With Diabetes Mellitus (WISDM), MOBILE, DEVOTE, SELECT, SOUL. She also designed and leads several investigator-initiated studies to unveil disease modifying agents for diabetes complications, and on the use of diabetes technologies to improve patients’ outcomes and diabetes care delivery funded by NIDDK and Industry . She is PI and the Chair of the Steering Committee of the NIDDK-funded U01 Diabetes Foot Consortium. Through her vision and leadership, she has built several cohorts of people with type 1 diabetes at Michigan that she leads and are at the intersection of several joint studies to identify heterogeneity in the risk of disease and complications, thus becoming one of the PIs of the Breakthrough T1D (former JDRF) Center of Excellence at the University of Michigan. She recently secured funding as PI for the new OHSU/Michigan Breakthrough T1D Center of Excellence to reverse cardio-renal complications in diabetes. She chaired the 2017 American Diabetes Association (ADA) Position Statement on Diabetic Neuropathy, the ADA Diabetes & Cardiovascular Disease Interest Group, and the ADA/ACC Heart Failure in Diabetes Consensus. As the ADA President for Medicine and Science she promoted research to understand the differences in the risk for complications in women with diabetes. Dr Busui has also a strong track record of mentorship and mentored numerous graduate and medical students, fellows, and early career faculty majority of which continued academic careers and secured independent funding. Dr. Busui has published more than 330 peer-reviewed manuscripts and 28 book chapters. She received awards for her research and advancement of diabetes care from many organizations including the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), the Fulbright Foundation, the Harvard Medical School, the Romanian Diabetes Society, and the University of Michigan.